Related Experiment Video
Updated: May 29, 2026
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Noscapine inhibits tumor growth in TMZ-resistant gliomas
Niyati Jhaveri1, Heeyeon Cho, Shering Torres
1Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, United States.
Abstract:
Noscapine, a common oral antitussive agent, has been shown to have potent antitumor activity in a variety of cancers. Treatment of glioblastoma multiforme (GBM) with temozolomide (TMZ), its current standard of care, is problematic because the tumor generally recurs and is then resistant to this drug. We therefore investigated the effects of noscapine on human TMZ-resistant GBM tumors. We found that noscapine significantly decreased TMZ-resistant glioma cell growth and invasion. Using the intracranial xenograft model, we showed that noscapine increased survival of animals with TMZ-resistant gliomas. Thus noscapine can provide an alternative therapeutic approach for the treatment of TMZ-resistant gliomas.
Insights
Noscapine effectively combats temozolomide-resistant glioblastoma multiforme (GBM). This antitussive agent reduces tumor growth and invasion, improving survival in preclinical models of resistant brain cancer.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis.
- Current standard-of-care temozolomide (TMZ) treatment often leads to tumor recurrence and drug resistance.
- There is a critical need for alternative therapeutic strategies for TMZ-resistant GBM.
Purpose of the Study:
- To investigate the efficacy of noscapine against human temozolomide-resistant glioblastoma.
- To evaluate noscapine's impact on glioma cell growth, invasion, and animal survival in preclinical models.
Main Methods:
- In vitro studies assessing noscapine's effects on TMZ-resistant glioma cell lines.
- In vivo intracranial xenograft models to evaluate noscapine's therapeutic potential in a GBM setting.
Main Results:
- Noscapine significantly inhibited the growth and invasion of TMZ-resistant glioma cells in vitro.
- Administration of noscapine prolonged the survival of animals bearing TMZ-resistant gliomas in vivo.
Conclusions:
- Noscapine demonstrates significant antitumor activity against TMZ-resistant glioblastoma.
- Noscapine represents a promising alternative therapeutic agent for treating recurrent and resistant forms of GBM.
